Clinical Trials

NCI and FDA announce joint program to streamline cancer drug development

Published in Medical Letter on the CDC and FDA, June 29th, 2003

Under an agreement between the U.S. Food and Drug Administration (FDA) and the National Cancer Institute (NCI), which is part of the U.S. National Institutes of Health (NIH), the two agencies will share knowledge and resources to facilitate the development of new cancer drugs and speed their delivery to patients.

FDA Commissioner Mark McClellan, MD, PhD, and NCI Director Andrew von Eschenbach, MD, said that they will establish a multipart Interagency Agreement to enhance the efficiency of clinical research and the scientific evaluation of new cancer medications. The planned agreement, announced formally at meeting of the American Society of Clinical Oncology in Chicago,...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA

Source: Medical Letter on the CDC and FDA (2003-06-29)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry